A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

Sadeleştirilmiş öğe sayfası
dc.contributor.authorAbali, Huseyin
dc.contributor.authorYalcin, Suayib
dc.contributor.authorOnal, Huseyin Cem
dc.contributor.authorDane, Faysal
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorArtac, Mehmet
dc.contributor.authorCamci, Celalettin
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorBasal, Fatma Bugdayci
dc.contributor.authorBudakoglu, Burcin
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorGoktas, Burce
dc.contributor.authorOzdener, Fatih
dc.contributor.authorCalisgan, Arzu
dc.date.accessioned2025-10-16T15:29:28Z
dc.date.issued2016
dc.description.abstractGastrointestinal Cancers Symposium, San Francisco, CA, JAN 21-23, 2016
dc.identifier.doi10.1200/jco.2016.34.4\_suppl.tps182
dc.identifier.otherWOS:000378109600176
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/8788
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleA study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS